ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer

Table 5 Impact of pS383/392-ATG4B expression levels on disease-free survival by the different demographic and clinicopathologic factors with colorectal cancer

Variable		No. (%)	CHR (95% CI)	p value*	AHR (95% CI)	p value ^†
Sex
Female	Low	35 (74.5)	1.00		1.00
Female	High	12 (25.5)	1.78 (0.76–4.85)	0.184	0.75 (0.29–1.94)	0.549^a
Male	Low	47 (66.2)	1.00		1.00
Male	High	24 (33.8)	4.00 (2.04–7.85)	< 0.001	3.37 (1.67–6.81)	0.001 ^a
Age, years
≦ 60	Low	29 (64.4)	1.00		1.00
≦ 60	High	16 (35.6)	2.96 (1.31–6.68)	0.009	1.39 (0.58–3.37)	0.464^a
>60	Low	53 (72.6)	1.00		1.00
>60	High	20 (27.4)	2.76 (1.41–5.39)	0.003	2.35 (1.15–4.78)	0.019 ^a
Cell differentiation
Well	Low	3 (75.0)	1.00		1.00
Well	High	1 (25.0)	434.45 (0.00-8.954E + 12)	0.616	Incalculable
Moderate, poor	Low	79 (69.3)	1.00		1.00
Moderate, poor	High	35 (30.7)	2.78 (1.65–4.69)	< 0.001	2.02 (1.15–3.56)	0.015 ^b
AJCC pathological stage
I, II	Low	50 (89.3)	1.00		1.00
I, II	High	6 (10.7)	4.55 (1.63–12.76)	0.004	4.59 (1.62–12.98)	0.004 ^c
III, IV	Low	32 (51.6)	1.00		1.00
III, IV	High	30 (48.4)	1.58 (0.85–2.94)	0.147	1.55 (0.83–2.89)	0.172^c
T classification
T1, T2	Low	21 (100.0)	1.00		1.00
T1, T2	High	0 (0.0)	Incalculable		Incalculable
T3, T4	Low	61 (62.9)	1.00		1.00
T3, T4	High	36 (37.1)	2.46 (1.43–4.21)	0.001	2.01 (1.16–3.48)	0.013 ^d
N classification
N0	Low	55 (85.9)	1.00		1.00
N0	High	9 (14.1)	4.92 (2.10–11.50)	< 0.001	4.38 (1.76–10.91)	0.001 ^e
N1, N2	Low	27 (50.0)	1.00		1.00
N1, N2	High	27 (50.0)	1.65 (0.83–3.28)	0.151	1.61 (0.80–3.21)	0.180^e
Postoperative RT
No	Low	79 (71.8)	1.00		1.00
No	High	31 (28.2)	3.51 (2.05–6.01)	< 0.001	2.51 (1.41–4.46)	0.002 ^a
Yes	Low	3 (37.5)	1.00		1.00
Yes	High	5 (62.5)	0.30 (0.03–3.36)	0.331	0.38(0.02–6.10)	0.490^a

Abbreviations: SCC, squamous cell carcinoma; CHR, crude hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio; AJCC, American Joint Committee on Cancer; RT, radiotherapy.
*p values were estimated by Cox’s regression.
^† p values were estimated by multivariate Cox’s regression.
^a Adjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs. stage I + II).
^b Adjusted for AJCC pathological stage (stage III + IV vs. stage I + II).
^c Adjusted for cell differentiation (moderate + poor vs. well).
^d Adjusted for cell differentiation (moderate + poor vs. well) and N classification (N1, N2 vs. N0).
^e Adjusted for cell differentiation (moderate + poor vs. well) and T classification (T3, T4 vs. T1 + T2).

ISSN: 1475-2867